Search - tctmd.com

Displaying 41 - 60 of 894

Sort: Relevancy | Date

News Daily News

Weekend Warriors Also See Mortality Benefits With Exercise

Michael O'Riordan

April 10, 2025

News Conference News ACC 2025

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

L.A. McKeown

April 10, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

Genetic Risk Score for Endothelial Cell Dysfunction Identifies Patients at Risk

News Daily News

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

Michael O'Riordan

February 27, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Yael L. Maxwell

February 14, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

L.A. McKeown

January 31, 2025

Presentation Controversies and Advances 2025

Familial Chylomicronemia Syndrome: Emerging Treatment Technologies

Presenter: Peter P. Toth

January 30, 2025

News Daily News

Athletes’ Hearts Also Require Careful Scrutiny, New Review Suggests

Yael L. Maxwell

January 17, 2025

News Features

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Michael O'Riordan

January 17, 2025

News Daily News

Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain

Yael L. Maxwell

January 13, 2025

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

Yael L. Maxwell

December 13, 2024

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

News Conference News AHA 2024

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Michael O'Riordan

November 21, 2024

News Conference News AHA 2024

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Caitlin E. Cox

November 21, 2024

Presentation AHA 2024

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Presenter: Steven E. Nissen

November 18, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

Presentation AHA 2024

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Presenter: Kausik K. Ray

November 17, 2024

Advertisement

Weekend Warriors Also See Mortality Benefits With Exercise

ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a)

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Cardiometabolic Trends Dominate First Round of Drugs Chosen for Medicare Price Negotiations

Familial Chylomicronemia Syndrome: Emerging Treatment Technologies

Athletes’ Hearts Also Require Careful Scrutiny, New Review Suggests

Weight-Loss Showdown: Is It Time for an RCT of Bariatric Surgery vs GLP-1s?

Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain

Top General Cardiology and Prevention News of 2024

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS

Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III

Phase 2 Trial of Zerlasiran: Multiple doses of an siRNA Targeting Lipoprotein(a) over 60 weeks

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

OptimiZation Of Lipid Lowering Therapies Using A Decision Support System In Patients With Acute Coronary Syndrome (ZODIAC): A Randomized Controlled Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content